Cargando…
Subcutaneous versus Intravenous Administration of Rituximab: Pharmacokinetics, CD20 Target Coverage and B-Cell Depletion in Cynomolgus Monkeys
The CD20-specific monoclonal antibody rituximab (MabThera(®), Rituxan(®)) is widely used as the backbone of treatment for patients with hematologic disorders. Intravenous administration of rituximab is associated with infusion times of 4–6 hours, and can be associated with infusion-related reactions...
Autores principales: | Mao, Cheng-Ping, Brovarney, Martin R., Dabbagh, Karim, Birnböck, Herbert F., Richter, Wolfgang F., Del Nagro, Christopher J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827219/ https://www.ncbi.nlm.nih.gov/pubmed/24265828 http://dx.doi.org/10.1371/journal.pone.0080533 |
Ejemplares similares
-
Pharmacokinetics and Bioavailability of a Therapeutic Enzyme (Idursulfase) in Cynomolgus Monkeys after Intrathecal and Intravenous Administration
por: Xie, Hongsheng, et al.
Publicado: (2015) -
Interleukin-21 Enhances Rituximab Activity in a Cynomolgus Monkey Model of B Cell Depletion and in Mouse B Cell Lymphoma Models
por: Krejsa, Cecile M., et al.
Publicado: (2013) -
Repeat-dose toxicity study of human umbilical cord mesenchymal stem cells in cynomolgus monkeys by intravenous and subcutaneous injection
por: Pan, Wei, et al.
Publicado: (2023) -
Repeated Intravaginal Inoculation of Zika Virus Protects Cynomolgus Monkeys from Subcutaneous Superchallenge
por: Shofa, Maya, et al.
Publicado: (2022) -
Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia
por: Gibiansky, Ekaterina, et al.
Publicado: (2021)